91 related articles for article (PubMed ID: 9112687)
21. Nucleosides and nucleotides. 177. 9-(6,7-dideoxy-beta-D-allo-hept-5- ynofuranosyl)adenine: a selective and potent ligand for P3 purinoceptor-like protein.
Matsuda A; Kosaki H; Saitoh Y; Yoshimura Y; Minakawa N; Nakata H
J Med Chem; 1998 Jul; 41(15):2676-8. PubMed ID: 9667957
[No Abstract] [Full Text] [Related]
22. A Purinergic Trail for Metastases.
Ferrari D; Malavasi F; Antonioli L
Trends Pharmacol Sci; 2017 Mar; 38(3):277-290. PubMed ID: 27989503
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory purinergic P2 receptor characterisation in rat distal colon.
Van Crombruggen K; Van Nassauw L; Timmermans JP; Lefebvre RA
Neuropharmacology; 2007 Aug; 53(2):257-71. PubMed ID: 17612577
[TBL] [Abstract][Full Text] [Related]
24. [New targets for drug therapeutics: receptors for purines and pyrimidines].
Ren LM; Zhang M; Yao SK; Zhu ZN
Sheng Li Ke Xue Jin Zhan; 2003 Apr; 34(2):116-20. PubMed ID: 12889142
[TBL] [Abstract][Full Text] [Related]
25. International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits.
Khakh BS; Burnstock G; Kennedy C; King BF; North RA; Séguéla P; Voigt M; Humphrey PP
Pharmacol Rev; 2001 Mar; 53(1):107-18. PubMed ID: 11171941
[TBL] [Abstract][Full Text] [Related]
26. Membrane compartments and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters.
Volonté C; D'Ambrosi N
FEBS J; 2009 Jan; 276(2):318-29. PubMed ID: 19076212
[TBL] [Abstract][Full Text] [Related]
27. P2Y receptors: biological advances and therapeutic opportunities.
Shaver SR
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):665-70. PubMed ID: 12825461
[TBL] [Abstract][Full Text] [Related]
28. P2 receptors and cancer.
White N; Burnstock G
Trends Pharmacol Sci; 2006 Apr; 27(4):211-7. PubMed ID: 16530853
[TBL] [Abstract][Full Text] [Related]
29. P2X and P2Y receptors as possible targets of therapeutic manipulations in CNS illnesses.
Köles L; Furst S; Illes P
Drug News Perspect; 2005 Mar; 18(2):85-101. PubMed ID: 15883618
[TBL] [Abstract][Full Text] [Related]
30. [The pharmacology of purine receptors].
Sergeev PV; Shimanovskiĭ NL
Farmakol Toksikol; 1987; 50(1):115-23. PubMed ID: 3549353
[No Abstract] [Full Text] [Related]
31. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.
Shabbir M; Ryten M; Thompson C; Mikhailidis D; Burnstock G
BJU Int; 2008 Feb; 101(3):352-9. PubMed ID: 18005209
[TBL] [Abstract][Full Text] [Related]
32. [Adenosine receptors. Principle for the development of new drugs].
Fischer I
Med Monatsschr Pharm; 1990 Jul; 13(7):202-3. PubMed ID: 2377132
[No Abstract] [Full Text] [Related]
33. Purinergic actions on neurons that modulate nociception in the rostral ventromedial medulla.
Selden NR; Carlson JD; Cetas J; Close LN; Heinricher MM
Neuroscience; 2007 Jun; 146(4):1808-16. PubMed ID: 17481825
[TBL] [Abstract][Full Text] [Related]
34. Purinoceptors modulating the release of noradrenaline.
von Kügelgen I
J Auton Pharmacol; 1994 Feb; 14(1):11-2. PubMed ID: 8150807
[No Abstract] [Full Text] [Related]
35. ATP and adenosine inhibit transmitter release at the frog neuromuscular junction through distinct presynaptic receptors.
Giniatullin RA; Sokolova EM
Br J Pharmacol; 1998 Jun; 124(4):839-44. PubMed ID: 9690879
[TBL] [Abstract][Full Text] [Related]
36. Proposal of a guanine-based purinergic system in the mammalian central nervous system.
Schmidt AP; Lara DR; Souza DO
Pharmacol Ther; 2007 Dec; 116(3):401-16. PubMed ID: 17884172
[TBL] [Abstract][Full Text] [Related]
37. The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications.
Antonioli L; Colucci R; Pellegrini C; Giustarini G; Tuccori M; Blandizzi C; Fornai M
Pharmacol Ther; 2013 Aug; 139(2):157-88. PubMed ID: 23588157
[TBL] [Abstract][Full Text] [Related]
38. ATP stimulates glucose transport through activation of P2 purinergic receptors in C(2)C(12) skeletal muscle cells.
Kim MS; Lee J; Ha J; Kim SS; Kong Y; Cho YH; Baik HH; Kang I
Arch Biochem Biophys; 2002 May; 401(2):205-14. PubMed ID: 12054471
[TBL] [Abstract][Full Text] [Related]
39. [Heterodimerization of G protein-coupled receptors].
Nakata H
Nihon Yakurigaku Zasshi; 2007 Jul; 130(1):4-8. PubMed ID: 17634672
[No Abstract] [Full Text] [Related]
40. Adenosine receptors.
Palmer TM; Stiles GL
Neuropharmacology; 1995 Jul; 34(7):683-94. PubMed ID: 8532135
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
